Publication | Open Access

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors

Angiogenesis3-Week DosingMedicineImmunologyAdvanced Solid TumorsImmune Checkpoint InhibitorVascular BiologyCancer TreatmentImmunotherapyOncologyRadiation Oncology